Does the media refer more to ACAD or BBIO?

In the previous week, BridgeBio Pharma had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for BridgeBio Pharma and 15 mentions for ACADIA Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 1.16 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ACAD?

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 15 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat Ascendis Pharma A/S's score of 1.13 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EXEL or ACAD?

In the previous week, Exelixis had 18 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 33 mentions for Exelixis and 15 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat Exelixis' score of 1.14 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACAD or BMRN?

In the previous week, BioMarin Pharmaceutical had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 15 mentions for ACADIA Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat ACADIA Pharmaceuticals' score of 1.16 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 17 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ACAD or HALO?

In the previous week, Halozyme Therapeutics had 15 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 30 mentions for Halozyme Therapeutics and 15 mentions for ACADIA Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 1.37 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 25 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$29.11 -0.62 (-2.09%)

As of 08/28/2026 04:00 PM Eastern

Compare

ACAD vs. BBIO, ASND, EXEL, BMRN, and HALO

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? ACADIA Pharmaceuticals's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BridgeBio Pharma's net margin of -97.03%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
BridgeBio Pharma	-97.03%	N/A	-61.19%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11
BridgeBio Pharma	$713.07M	21.00	-$724.93M	-$3.57	N/A

In the previous week, BridgeBio Pharma had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for BridgeBio Pharma and 15 mentions for ACADIA Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 1.16 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals presently has a consensus target price of $34.36, suggesting a potential upside of 18.04%. BridgeBio Pharma has a consensus target price of $100.79, suggesting a potential upside of 31.58%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

ACADIA Pharmaceuticals and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Ascendis Pharma A/S has a net margin of 70.99% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Ascendis Pharma A/S's return on equity of 32.54% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 15 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat Ascendis Pharma A/S's score of 1.13 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.99	-$258M	$12.89	19.23
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ascendis Pharma A/S presently has a consensus price target of $302.68, indicating a potential upside of 22.09%. ACADIA Pharmaceuticals has a consensus price target of $34.36, indicating a potential upside of 18.04%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Ascendis Pharma A/S beats ACADIA Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 8.05%. ACADIA Pharmaceuticals has a consensus price target of $34.36, suggesting a potential upside of 18.04%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

Exelixis has a net margin of 35.33% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Exelixis' return on equity of 42.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

In the previous week, Exelixis had 18 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 33 mentions for Exelixis and 15 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat Exelixis' score of 1.14 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exelixis has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.54	$782.57M	$3.18	17.12
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11

Summary

Exelixis beats ACADIA Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

ACADIA Pharmaceuticals has higher earnings, but lower revenue than BioMarin Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11
BioMarin Pharmaceutical	$3.41B	3.67	$348.90M	$0.37	174.78

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BioMarin Pharmaceutical's net margin of 2.14%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

ACADIA Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 15 mentions for ACADIA Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat ACADIA Pharmaceuticals' score of 1.16 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	17 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ACADIA Pharmaceuticals currently has a consensus target price of $34.36, suggesting a potential upside of 18.04%. BioMarin Pharmaceutical has a consensus target price of $88.79, suggesting a potential upside of 37.30%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats BioMarin Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

ACADIA Pharmaceuticals presently has a consensus target price of $34.36, suggesting a potential upside of 18.04%. Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 13.43%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Halozyme Therapeutics' net margin of 24.86%. Halozyme Therapeutics' return on equity of 260.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Halozyme Therapeutics	24.86%	260.98%	23.91%

In the previous week, Halozyme Therapeutics had 15 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 30 mentions for Halozyme Therapeutics and 15 mentions for ACADIA Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 1.37 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	25 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher earnings, but lower revenue than Halozyme Therapeutics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11
Halozyme Therapeutics	$1.40B	8.56	$316.89M	$3.35	31.45

Summary

Halozyme Therapeutics beats ACADIA Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.02B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	13.11	11.62	273.16	25.45
Price / Sales	4.68	1,295.88	605.00	76.62
Price / Cash	32.81	106.39	76.74	53.00
Price / Book	3.84	16.53	12.98	6.14
Net Income	$391M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.32%	-0.31%	0.13%	-0.80%
1 Month Performance	9.64%	9.80%	7.08%	4.13%
1 Year Performance	12.00%	55.66%	24.67%	15.17%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.6828 of 5 stars	$29.11 -2.1%	$34.36 +18.0%	+12.0%	$5.02B	$1.07B	13.11	510	Positive News Analyst Forecast
BBIO BridgeBio Pharma	3.4598 of 5 stars	$81.07 -0.5%	$100.79 +24.3%	+48.0%	$15.93B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.7031 of 5 stars	$251.95 -0.5%	$300.33 +19.2%	+27.6%	$15.80B	$814.57M	19.55	1,189	Analyst Forecast Analyst Revision
EXEL Exelixis	3.1006 of 5 stars	$54.55 +0.9%	$50.07 -8.2%	+45.5%	$13.40B	$2.32B	17.15	1,077	Trending News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9111 of 5 stars	$65.07 -2.4%	$88.83 +36.5%	+11.0%	$12.91B	$3.22B	175.86	3,221	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, EXEL, BMRN, and HALO

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, EXEL, BMRN, and HALO

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Is ACAD or BBIO more profitable?

Do institutionals and insiders believe in ACAD or BBIO?

Which has more volatility and risk, ACAD or BBIO?

Which has preferable earnings and valuation, ACAD or BBIO?

Does the media refer more to ACAD or BBIO?

Do analysts rate ACAD or BBIO?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Is ASND or ACAD more profitable?

Does the media prefer ASND or ACAD?

Which has more volatility & risk, ASND or ACAD?

Which has stronger earnings and valuation, ASND or ACAD?

Do insiders & institutionals have more ownership in ASND or ACAD?

Do analysts prefer ASND or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Exelixis?

Which has more risk & volatility, EXEL or ACAD?

Do analysts prefer EXEL or ACAD?

Is EXEL or ACAD more profitable?

Does the media favor EXEL or ACAD?

Do insiders & institutionals believe in EXEL or ACAD?

Which has preferable valuation and earnings, EXEL or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Which has stronger valuation & earnings, ACAD or BMRN?

Is ACAD or BMRN more profitable?

Which has more risk and volatility, ACAD or BMRN?

Does the media refer more to ACAD or BMRN?

Do analysts recommend ACAD or BMRN?

Do institutionals and insiders hold more shares of ACAD or BMRN?

Summary

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

Do insiders and institutionals hold more shares of ACAD or HALO?

Which has more risk & volatility, ACAD or HALO?

Do analysts prefer ACAD or HALO?

Is ACAD or HALO more profitable?

Does the media favor ACAD or HALO?

Which has stronger valuation and earnings, ACAD or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools